Get the Stockscreener App
6.69
2.76%
-0.19
After Hours:
6.69
Gh Research Plc stock is traded at $6.69, with a volume of 113.55K.
It is down -2.76% in the last 24 hours and down -36.29% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
See More
Previous Close:
$6.88
Open:
$6.82
24h Volume:
113.55K
Relative Volume:
3.01
Market Cap:
$341.04M
Revenue:
-
Net Income/Loss:
$-32.32M
P/E Ratio:
-9.738
EPS:
-0.687
Net Cash Flow:
$-36.14M
1W Performance:
-4.29%
1M Performance:
-36.29%
6M Performance:
-37.24%
1Y Performance:
-33.43%
1-Day Range:
$6.39
$6.8409
1-Week Range:
$6.39
$7.92
52-Week Range:
$5.05
$14.99
Gh Research Plc Stock (GHRS) Company Profile
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
When (GHRS) Moves Investors should Listen - Stock Traders Daily
Lynx1 Capital Management LP Has $46.25 Million Holdings in GH Research PLC (NASDAQ:GHRS) - MarketBeat
ACTH and GH Function Tests Market – Industry Forecast and Growth Potential - Elektrotransports.lv
Magic mushroom market set to go gangbusters, Irish researcher says - Mugglehead
(GHRS) Investment Report - Stock Traders Daily
Guardant Health (NASDAQ:GH) Shares Down 3.5% - Defense World
GH Research Engages Investors at Healthcare Conference - TipRanks
GH Research to Engage at Global Investment Conference - TipRanks
GH Research PLC (NASDAQ:GHRS) to Post FY2024 Earnings of ($0.75) Per Share, HC Wainwright Forecasts - Defense World
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
HC Wainwright Weighs in on GH Research PLC's FY2024 Earnings (NASDAQ:GHRS) - MarketBeat
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials - MSN
GH Research (NASDAQ:GHRS) Receives Buy Rating from HC Wainwright - Defense World
GH Research (NASDAQ:GHRS) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials - Benzinga
GH Research (NASDAQ:GHRS) Receives Market Outperform Rating from JMP Securities - Defense World
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates - Yahoo Finance UK
JMP Securities Reaffirms Market Outperform Rating for GH Research (NASDAQ:GHRS) - MarketBeat
GH Research (NASDAQ:GHRS) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Trend Tracker for (GHRS) - Stock Traders Daily
GH Research names new CEO amid clinical trials - Investing.com India
GH Research to Connect at Global Healthcare Conference - TipRanks
GH Research (NASDAQ:GHRS) Shares Gap Down to $10.50 - MarketBeat
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
GH Research names new CEO amid clinical trials By Investing.com - Investing.com Canada
GH Research names new CEO amid clinical trials - Investing.com
GH Research’s losses persist as it tries to lift FDA hold for GH001 - Green Market Report
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer - Yahoo Finance UK
GH Research Appoints New CEO, Advances Trials - TipRanks
GH Research appoints Velichka Valcheva to CEO - TipRanks
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates - StockTitan
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer - GlobeNewswire
Gemini Therapeutics (NASDAQ:GMTX) versus GH Research (NASDAQ:GHRS) Head-To-Head Review - Defense World
Seagate Technology Holdings plc (NASDAQ:STX) Given Consensus Recommendation of “Hold” by Analysts - Defense World
GH Research (NASDAQ:GHRS) Shares Gap Down to $11.04 - MarketBeat
GH Research (NASDAQ:GHRS) Shares Down 4% - MarketBeat
GH Research (NASDAQ:GHRS) Trading Up 2.6% - MarketBeat
Castings P.L.C. (LON:CGS) Insider Steve Mant Purchases 3,230 Shares - Defense World
GH Research (NASDAQ:GHRS) Shares Gap Up to $10.57 - MarketBeat
Amenfiman Rural Bank deposit hits GH₵1billion highest in the rural banking industry - Myjoyonline
Tullow Oil Plc (TLW.gh) HY2024 Interim Report - AfricanFinancials
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer - Business Wire
HC Wainwright Reiterates “Buy” Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
GH Research PLC (NASDAQ:GHRS) to Post Q1 2025 Earnings of ($0.21) Per Share, HC Wainwright Forecasts - MarketBeat
GH Research (NASDAQ:GHRS) Given “Buy” Rating at HC Wainwright - Defense World
Symrise (OTCMKTS:SYIEY) Reaches New 1-Year High at $31.68 - Defense World
Hallador Energy (NASDAQ:HNRG) Short Interest Update - Defense World
Investment Analysts’ Weekly Ratings Changes for Lamb Weston (LW) - Defense World
Schroder European Real Estate Investment Trust (LON:SERE) Shares Up 0.9% - Defense World
GH Research PLC (NASDAQ:GHRS) Short Interest Update - Defense World
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):